Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVALUATION OF DRUG-DRUG INTERACTION BETWEEN THE NOVEL cPLA2 INHIBITOR AK106-001616 AND METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS.

Trial Profile

EVALUATION OF DRUG-DRUG INTERACTION BETWEEN THE NOVEL cPLA2 INHIBITOR AK106-001616 AND METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AK 106-001616 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Asahi Kasei; Asahi Kasei Pharma America Corp
  • Most Recent Events

    • 09 Apr 2014 New trial record
    • 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top